Navidea to sell ‘Cardinal Milestone Payment’ for $8M, gets $2.75M credit line

Navidea Biopharmaceuticals announces the execution of a letter of intent to sale the Cardinal Milestone Payment for $8M and execution of a new $2.75M Equity Line of Credit, led by a longtime Navidea investor, to provide substantial funding for the Company’s Phase IIb and Phase III trials and expand operations. The Company’s uniquely structured capital raise will provide access to up to $10.75M and propels the organization forward by providing substantial funding for the Company’s current Phase IIb and Phase III trials. Working closely together with its trusted partner and longtime investor, the Company has agreed to sell the Cardinal Milestone Payment for $8Mn, subject to execution of final documentation. This sale will bring in immediate capital into the company, along with access up to $2.75M with use of an Equity Line of Credit. This powerful combination of capital access allows the Company to expand its clinical trial base – driving additional shareholder value. "This capital infusion provides an immediate and positive impact on the trajectory of the Company’s pioneering work – empowering accelerated progress in areas of focus for 2023 and 2024," said Dr. Jason Myers. "G2G and Navidea, now with the added support of this new partnership, are excited to demonstrate our combined ability to advance innovative science and drive shareholder return." "Our goal is to partner with trusted investors who share our vision to drive Phase IIb and Phase III trials to completion, enhance our operational capabilities, and continue our strategy of cultivating growth," said Board of Directors, Director Josh Wilson. "This partnership and structure creates exceptional enterprise value and provides the fuel needed for growth now and into the future."